Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00473915 · ClinicalTrials.gov registry record · Phase 4

Intranasal Steroids and the Nasal Ocular Response

A Phase 4 study of Seasonal Allergic Rhinitis, sponsored by University of Chicago.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT00473915 is a Phase 4 study of Seasonal Allergic Rhinitis that has completed, run by University of Chicago. The registered enrollment target is 20 participants, below the 667-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00473915, a Phase 4 study of Seasonal Allergic Rhinitis, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Eye symptoms of tearing, redness and itch frequently occur in patients with allergic rhinitis or hayfever. The purpose of this study is to learn whether placing allergen (the substance that causes allergies) in the nose several days in a row will cause an increase in eye symptoms and whether receiving a nasal steroid spray will prevent these eye symptoms.

Conditions Studied

Interventions

  • DRUG fluticasone furoate

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2007-04
Est. Completion 2008-02
Phase Phase 4

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT00473915

The ClinicalTrials.gov registry entry for NCT00473915 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 667-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (97% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which fluticasone furoate is the first listed.

NCT00473915 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00473915 about?

NCT00473915 is a clinical study titled "Intranasal Steroids and the Nasal Ocular Response". Eye symptoms of tearing, redness and itch frequently occur in patients with allergic rhinitis or hayfever. The purpose of this study is to learn whether placing allergen (the substance that causes allergies) in the nose several days in a row will cause an increase in eye symptoms and whether receivi...

What is the current status of trial NCT00473915?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2007-04. Estimated completion is 2008-02.

What conditions does trial NCT00473915 study?

This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.

What interventions are being tested in trial NCT00473915?

The interventions under investigation include: fluticasone furoate (DRUG).

Who is sponsoring clinical trial NCT00473915?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00473915 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seasonal Allergic Rhinitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.